JP2013515033A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515033A5
JP2013515033A5 JP2012545277A JP2012545277A JP2013515033A5 JP 2013515033 A5 JP2013515033 A5 JP 2013515033A5 JP 2012545277 A JP2012545277 A JP 2012545277A JP 2012545277 A JP2012545277 A JP 2012545277A JP 2013515033 A5 JP2013515033 A5 JP 2013515033A5
Authority
JP
Japan
Prior art keywords
diazaspiro
undecan
quinoxalin
methyl
ring system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012545277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515033A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/070263 external-priority patent/WO2011076747A1/en
Publication of JP2013515033A publication Critical patent/JP2013515033A/ja
Publication of JP2013515033A5 publication Critical patent/JP2013515033A5/ja
Pending legal-status Critical Current

Links

JP2012545277A 2009-12-21 2010-12-20 オレキシン受容体アンタゴニストとしてのジアザ−スピロ[5.5]ウンデカン類 Pending JP2013515033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2663DE2009 2009-12-21
IN2663/DEL/2009 2009-12-21
PCT/EP2010/070263 WO2011076747A1 (en) 2009-12-21 2010-12-20 Diaza-spiro[5.5]undecanes as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2013515033A JP2013515033A (ja) 2013-05-02
JP2013515033A5 true JP2013515033A5 (enExample) 2014-01-30

Family

ID=43640117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545277A Pending JP2013515033A (ja) 2009-12-21 2010-12-20 オレキシン受容体アンタゴニストとしてのジアザ−スピロ[5.5]ウンデカン類

Country Status (9)

Country Link
US (1) US8530648B2 (enExample)
EP (1) EP2516439B1 (enExample)
JP (1) JP2013515033A (enExample)
CN (1) CN102762567A (enExample)
AR (1) AR079553A1 (enExample)
ES (1) ES2459496T3 (enExample)
TW (1) TW201132642A (enExample)
UY (1) UY33125A (enExample)
WO (1) WO2011076747A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
WO2015113057A1 (en) * 2014-01-27 2015-07-30 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN106831774B (zh) * 2017-02-07 2019-02-01 上海合全药业股份有限公司 一种(6s,7s)-9-叔丁氧羰基-7-(三氟甲基)-2,9-二氮杂螺[5.5]十一烷的合成方法
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
SG11202106108WA (en) * 2019-01-28 2021-08-30 Suntory Holdings Ltd Composition for competitive inhibition of orexin receptors
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2023012971A (es) * 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.
AU2022376760A1 (en) * 2021-10-27 2024-05-02 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
US20240425519A1 (en) * 2021-11-04 2024-12-26 University Of Washington Novel spirocyclic compounds as klhdc2 ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
JP2009506061A (ja) * 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
PT1961744E (pt) * 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização

Similar Documents

Publication Publication Date Title
KR101811549B1 (ko) 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
KR100854174B1 (ko) Gaba 수용체에 대한 리간드로서의 벤즈이미다졸 및피리딜이미다졸 유도체
JP5039268B2 (ja) ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
JP7357932B2 (ja) Crhr2拮抗薬としての縮合環状尿素誘導体
JP2013515032A5 (enExample)
JP2013515033A (ja) オレキシン受容体アンタゴニストとしてのジアザ−スピロ[5.5]ウンデカン類
JP2019504821A (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
US20170107204A1 (en) Trka kinase inhibitors, compositions and methods thereof
EP3186233A1 (en) Probes for imaging huntingtin protein
WO2015017610A1 (en) Syk inhibitors
WO2012017020A1 (en) N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
MX2010013920A (es) Alcoholes alquinilicos como inhibidores de cinasas.
KR20150143479A (ko) Fasn 억제용 신규 화합물 및 조성물
US20120165331A1 (en) Di/tri-aza-spiro-C9-C11alkanes
US11814384B2 (en) Inhibtors of Raf kinases
EA037598B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
IL293191A (en) Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
KR20150130311A (ko) 야누스 키나제 억제제로서의 n-(2-시아노 헤테로시클릴)피라졸로 피리돈
TW202509019A (zh) Sarm1調節子、其製劑及用途
JP2026503588A (ja) 新規alpk1阻害剤
JP2017226661A (ja) 脆弱x症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体
RU2778641C2 (ru) Производные конденсированной циклической мочевины в антагонист crhr2
HK40037565A (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109B (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109A (en) Fused cyclic urea derivatives as crhr2 antagonist